Downregulation of the RUNX3 expression rate in tumour was 74.7% (65 in 87 cases) in the GCI group, 82.1% (24 in 28 cases) in the RB group, and 85.7% (18 in 21 cases) in the RM group. Here, RUNX3 is linked to neoplasm.